IL6 and neoplasm: As depicted in Figure 5 and in line with our previous findings, tumor-derived constitutive NLRP3 activity induces IL-1β and IL-6 in bone marrow and spleen cells (16), we show that tumor-bearing mice treated with OLT1177 reveal reductions in both total STAT3 as well as pSTAT3 (Y705) in bone marrow cells.